Loading
Thyroid Cancer Diagnosis and Treatment / Management of Metastatic Bone Disease · Journal article
Future Oncology · August 10, 2026
Encouraging direction, but not yet definitive.
This retrospective cohort identifies brain metastasis and other-site metastases as independent poor prognostic factors for overall survival in radioiodine-refractory DTC patients. In non-refractory patients, stimulated thyroglobulin ≤75 ng/mL showed predictive sensitivity and specificity for favorable treatment response, though this finding is limited by retrospective design and reliance on a surrogate marker.
Retrospective cohort study. Patients with distant metastases of differentiated thyroid cancer undergoing radioiodine therapy. No specific eligibility criteria stated in abstract.. Intervention: Radioiodine therapy (RAIT). Compared with: Stratified comparison between RAIR and NRAIR subgroups; no external control arm. n = 146.
In RAIR patients, brain metastasis was an independent poor prognostic factor (HR = 5.49, 95% CI: 1.46–20.66, p = 0.012) In RAIR patients, other-site metastases was an independent poor prognostic factor (HR = 4.11, 95% CI: 1.06–15.85, p = 0.004) In NRAIR patients, sTg ≤75 ng/mL predicted favorable treatment response with sensitivity 84.8% and specificity 78.9%
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
For RAIR-DTC patients, presence of brain or other-site metastases should prompt intensified monitoring and consideration of alternative therapies. In NRAIR patients, sTg threshold may help predict treatment response, though validation in prospective cohorts is needed before clinical implementation.
Retrospective cohort study with clear stratification and identified prognostic factors in radioiodine-refractory DTC, but limited by single-centre design, modest sample size, and surrogate endpoint assessment in the non-refractory group.
As stated by the source record.
Quoted from the source exactly as published.
For RAIR-DTC patients, presence of brain or other-site metastases should prompt intensified monitoring and consideration of alternative therapies. In NRAIR patients, sTg threshold may help predict treatment response, though validation in prospective cohorts is needed before clinical implementation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Aims Patients with distant metastases of differentiated thyroid cancer (DM-DTC) exhibit significant heterogeneity in clinical characteristics and prognosis. This study aimed to investigate prognostic variables affecting overall survival (OS) in radioiodine-refractory (RAIR) patients and to predict the radioiodine therapy (RAIT) response and stimulated thyroglobulin (sTg) levels in non-radioiodine-refractory (NRAIR) patients.Methods A retrospective analysis was conducted on 146 patients of DM-DTC undergoing RAIT, categorizing them into an RAIR group (n = 56) and an NRAIR group (n = 90). Kaplan-Meier assessed survival, Cox regression identified RAIR prognostic factors, and logistic regression explored sTg-treatment response in NRAIR.Results The median follow-up period was 71 months (IQR: 24–132 months).In RAIR, brain metastasis (HR = 5.49, 95% CI: 1.46–20.66, p = 0.012) and other-site metastases (HR = 4.11, 95% CI: 1.06–15.85, p = 0.004) were independent poor prognostic factors. In NRAIR, sTg ≤ 75 ng/mL predicted favorable response (sensitivity 84.8%, specificity 78.9%).Conclusions RAIR status significantly impacts DM-DTC prognosis. Brain metastases or other-site metastases are independent prognostic factors in RAIR patients, highlighting the need for stratified treatment. In NRAIR patients, preliminary data suggest that sTg ≤ 75 ng/mL predicts a favorable treatment response.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.